Skip to content
PeptideGeek

Weight loss

Pemvidutide, explained simply

A dual-action weekly injection in trials for obesity and fatty liver disease — designed to burn liver fat while driving weight loss.

Some human studiesInjection under the skin (like insulin shots)7 cited sourcesResearch compound — not FDA approved

Start here

What is Pemvidutide?

Pemvidutide is an injectable peptide being developed for weight loss and for MASH, a serious form of fatty liver disease. It activates two hormone receptors in equal balance: GLP-1, which curbs appetite, and glucagon, which increases the fat the liver burns. In trials it produced up to 15.6% weight loss without the gradual dose increases most similar drugs require, and the FDA has granted it Breakthrough Therapy status for MASH. It is still in Phase 1-2 human trials — a research compound, not an approved medicine.

How it works in your body

Pemvidutide works through two hormone receptors at the same time: GLP-1 (a gut hormone that tells your brain you're full) and glucagon 35. The GLP-1 side quiets appetite so you eat less; the glucagon side tells the liver to burn more fat and raises the energy your body uses at rest. Attacking weight from both directions — less coming in, more being burned — is what makes the combination effective.

The deeper mechanism, for the curious

Pemvidutide is a lab-made peptide that switches on two receptors at the same time, the GLP-1 (a gut hormone that tells your brain you're full) receptor (GLP-1R) and the glucagon receptor (GcgR). Both are Gs-coupled GPCRs (a kind of cell-surface receiver), and both raise cAMP (a messenger molecule inside cells) and turn on PKA signaling (a chain of signals inside the cell). When GLP-1R is activated in POMC neurons of the hypothalamus (the brain region that runs your hormone system) and NTS neurons of the hindbrain (two groups of brain cells that control appetite), it sends signals that reduce appetite and increase fullness. When GcgR is activated in hepatocytes (liver cells), it increases gluconeogenesis (making new sugar) and lipolysis (breaking down fat). This promotes burning of fat in the liver and a faster metabolic rate (calorie burn). Hitting both targets produces weight loss that works together to beat drugs that hit only GLP-1R. The GLP-1R part provides appetite suppression (about 15-20% potential weight loss), while the GcgR part speeds up metabolism and fat release (about 8-15% additional weight loss). GLP-1R activation also increases glucose-dependent insulin secretion (insulin release that happens only when blood sugar is high), while both pathways help control how much sugar the liver makes.

Evidence check

Some human studies

It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.

Every numbered marker on this page links to one of the 7 sources at the bottom.

92/100

Weight Loss

Phase 2b MOMENTUM trial demonstrated 15.6% body weight loss at 2.4 mg without dose titration, rivaling titrated competitors.

95/100

Liver Health

IMPACT trial showed 58% MASH resolution rate and up to 68.5% relative liver fat reduction at 12 weeks, earning FDA Breakthrough Therapy designation.

88/100

Metabolic Health

Balanced action on both the GLP-1 and glucagon receptors improves blood fats (lipid profiles), insulin sensitivity, blood pressure, and liver markers across the board.

What the research points to

The most-asked question

How much Pemvidutide do I take?

Pemvidutide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 1.8 mg, once daily.

  1. 48 weeks

    1.2 mg

    • How often
      Once weekly
    • Used for
      Weight management, MASH
    • How
      Injection under the skin

    Lowest dose studied; given at full strength from week 1 with no titration (stepping the dose up gradually). Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial 6 and is the lower MASH dose in the IMPACT Phase 2b trial 7.

  2. 48 weeks

    1.8 mg

    • How often
      Once weekly
    • Used for
      Weight management, MASH
    • How
      Injection under the skin

    Mid dose, started at full strength with no titration (stepping the dose up gradually); ~11% weight loss at 48 weeks (MOMENTUM) 6 and the higher MASH dose in IMPACT 7.

  3. 48 weeks

    2.4 mg

    • How often
      Once weekly
    • Used for
      Maximal weight loss
    • How
      Injection under the skin

    Highest dose; reached via a 4-week titration (stepping the dose up gradually) in MOMENTUM, where it produced 15.6% weight loss at 48 weeks 6.

Each step of the schedule, drawn on one scale — 0 to 2.4 mg.
  1. 48 weeks1.2 mg
  2. 48 weeks1.8 mg
  3. 48 weeks2.4 mg

Adjusting your dose

You're at the right dose if…

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Consider going up if…

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Go down if…

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

The ceiling: 2.4 mg (as determined by your healthcare provider based on individual response and tolerance)

Reconstitution, in plain words

How do I mix Pemvidutide?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Pemvidutide:

What you need

  • Pemvidutide vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

A worked example

Add the recommended volume of bacteriostatic water to the Pemvidutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Working out your dose

Your dose of Pemvidutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Pemvidutide's recorded schedule.

PemvidutideOnce weekly

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Injection sites & technique

Where do I inject Pemvidutide?

The best spots

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

How to do it, step by step

  • Wash your hands thoroughly with soap and water before handling supplies
  • Clean the injection site with an alcohol swab and let it air dry completely
  • Pinch a fold of skin at the chosen injection site
  • Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
  • Inject the medication slowly and steadily over 5-10 seconds
  • Release the skin fold and remove the needle, applying gentle pressure with a clean swab
  • Rotate injection sites to prevent tissue irritation or lipodystrophy (lumps or dents in the fat under the skin)
  • Dispose of the needle safely in a sharps container—never recap or reuse needles

Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Timing

When do I take Pemvidutide?

Best time of day

Administer Pemvidutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.

With or without food?

Pemvidutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.

Taking it with other peptides

Pemvidutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

The honest list

What side effects could Pemvidutide cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

  • Nausea

    Most commonly reported adverse event, generally mild and often resolving within the first few weeks of treatment.

    What to do Eat smaller, more frequent meals. Avoid high-fat or greasy foods. Stay well hydrated.

  • Diarrhea

    Mild to moderate gastrointestinal disturbance occurring in a meaningful proportion of trial participants.

    What to do Maintain hydration, consider bland diet temporarily, and consult prescriber if persistent beyond 2 weeks.

  • Headache

    Reported in clinical trials, typically mild and self-resolving without intervention.

    What to do Standard analgesics as needed. Ensure adequate hydration and regular meals.

Less common

Worth knowing about, but most people never see these.

  • Vomiting

    Less frequent than nausea; may occur during the initial treatment period despite no titration (stepping the dose up gradually) requirement.

    What to do Take medication with a light snack. Antiemetic medication if recurrent. Dose reduction may be considered.

  • Decreased Appetite

    Pharmacological effect supporting weight loss but may require monitoring for adequate nutritional intake.

    What to do Track caloric and protein intake. Consider nutritional counseling to ensure micronutrient sufficiency.

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

  • Sudden inflammation of the pancreas (acute pancreatitis)

    Rare but serious risk consistent with the GLP-1 receptor agonist (a drug that mimics the gut's fullness hormone) class. Requires immediate clinical evaluation.

    What to do Discontinue pemvidutide immediately. Seek emergency medical attention. Do not rechallenge after confirmed pancreatitis.

  • Severe stomach and gut problems

    Combined GLP-1R and GcgR activation can produce potent GI effects including severe nausea, vomiting, diarrhea, and abdominal pain, potentially leading to dehydration or electrolyte imbalances.

    What to do Use gradual dose titration (stepping the dose up gradually) schedule; administer with food to reduce nausea; ensure adequate hydration and electrolyte replacement; consider antiemetics; monitor for signs of dehydration; educate on expected GI effects during titration.

Week by week

What should I expect from Pemvidutide, and when?

  1. Weeks 1-4

    You might notice
    • Full therapeutic dose from day one (no titration (stepping the dose up gradually))
    • Early appetite reduction and gastrointestinal adjustment
    • Initial weight loss of 3-5% typically observed
    • Liver fat reduction begins
    What's normal
    • Full integration of Pemvidutide into physiological systems is established
    • Long-term Pemvidutide response remains personalized to your physiology
    • Pemvidutide tolerance is well-maintained with consistent dosing
    What's next
    • Maintain your established Pemvidutide protocol for sustained benefits
    • Continue periodic monitoring to confirm Pemvidutide efficacy
    • Review comprehensive Pemvidutide response with your provider

  2. Weeks 4-24

    You might notice
    • Progressive weight loss reaches 8-12%
    • Significant liver fat reduction (up to 75% relative decrease by MRI)
    • Improvements in transaminases and metabolic parameters become apparent
    • MASH resolution observed in clinical studies
    What's normal
    • Levels of Pemvidutide in your body have now reached a steady plateau
    • Measurable changes that fit how it works may start to appear
    • Early adjustment effects usually settle by this point
    What's next
    • Maintain Pemvidutide dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team

  3. Weeks 24-48+

    You might notice
    • Weight loss continues toward its plateau of 13-16%
    • Lasting improvements in liver tissue (seen on biopsy), blood fats, and heart-risk markers
    • Metabolic benefits continue with ongoing treatment
    What's normal
    • Characteristic effects of Pemvidutide are becoming established
    • Repeated Pemvidutide doses show predictable pharmacological effects
    • Pemvidutide tolerance patterns are developing normally
    What's next
    • Evaluate Pemvidutide efficacy relative to treatment goals
    • Discuss potential protocol adjustments with your healthcare provider
    • Continue regular Pemvidutide monitoring at current frequency

How to tell it's actually working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Pemvidutide over time
  • Reduction in symptom frequency or severity

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing anything? The usual reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Is it right for you?

Who should avoid Pemvidutide?

Do not use it if…

  • Personal or family history of medullary thyroid carcinoma (a thyroid cancer) or MEN2 syndrome (an inherited condition that causes tumors in hormone glands)
  • Known allergy to pemvidutide or formulation components
  • History of acute pancreatitis (sudden inflammation of the pancreas)
  • Severe liver failure (Child-Pugh C cirrhosis, the most advanced stage of liver scarring)

Be extra careful if…

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Pemvidutide use
  • You have any chronic health conditions that require regular monitoring

When to stop

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Pemvidutide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Pemvidutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

What it mixes badly (and well) with

Medications

  • Avoid
    Other GLP-1 Receptor Agonists

    Use with caution—discuss with your healthcare provider.

  • Avoid
    Sulfonylureas

    Use with caution—discuss with your healthcare provider.

  • Avoid
    Insulin (without dose adjustment)

    Use with caution—discuss with your healthcare provider.

Other peptides

  • OK together
    Metformin

    May be used together under medical guidance.

  • OK together
    Structured Exercise Program

    May be used together under medical guidance.

  • OK together
    Vitamin E (for MASH patients)

    May be used together under medical guidance.

Supplements

  • OK together
    Multivitamins

    Generally safe to take alongside Pemvidutide. Space doses apart if taking oral formulations to ensure optimal absorption.

  • OK together
    Electrolyte supplements

    Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Who it tends to suit

Adults seeking substantial weight loss without a slow step-up in dose

Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration (stepping the dose up gradually). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

People with both fatty liver disease (MASH/NAFLD) and obesity who need a drug that acts on two targets

Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 13.

People with metabolic syndrome (a cluster of weight, blood sugar, blood pressure, and cholesterol problems) who need broad risk-factor improvement

Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Those interested in experimental drugs that act on two targets, with strong early results

Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist (a compound that switches a receptor on) therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach 13.

The safety picture overall

Pemvidutide (ALT-801, developed by Altimmune; a drug that activates both the GLP-1 (a gut hormone that tells your brain you're full) and glucagon receptors) 35 completed Phase IIb obesity trials with a favorable heart-safety profile. Stomach and gut side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects. They are more common than with GLP-1 drugs alone because of the added glucagon receptor activation. Pancreatitis (inflammation of the pancreas) risk and raised calcitonin levels (a thyroid hormone) need monitoring. There were no serious heart safety signals despite the dual action. Heart rate rose by 5-10 bpm.

Phase IIb randomized controlled trials (n=500+) support the dual GLP-1 (a gut hormone that tells your brain you're full) receptor/glucagon receptor mechanism, with correction of high blood sugar and weight loss up to 18% over 52 weeks. Fasting blood fat tests showed 20-30% lower triglycerides and 10-15% lower LDL, measured with standard cholesterol panels. Studies using indirect calorimetry (measuring calories burned) show higher energy expenditure. Pancreatic MRI shows no structural changes.

Keeping it good

How do I store Pemvidutide?

Before mixing (powder)

Store Pemvidutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After mixing (liquid)

Once reconstituted, Pemvidutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs it has gone bad

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Not our opinion — the published record

What the studies actually found about Pemvidutide

2025

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Pemvidutide, a drug that acts on two targets (GLP-1 and glucagon), cleared MASH (a fatty liver disease with inflammation) without worsening liver scarring in 58% of patients at the 1.2 mg dose, versus 20% on placebo, after 24 weeks. Both doses were safe, with mostly mild stomach and gut side effects.

Noureddin M, et al.

If this isn't the right fit

What people use instead of Pemvidutide

Alternative approaches for weight management support

  • Consult your healthcare provider for alternatives to Pemvidutide based on your specific needs and medical history

Alternative weight management approaches

  • Semaglutide (Wegovy/Ozempic)
  • Liraglutide (Saxenda)
  • AOD-9604

Non-injectable weight management

  • Oral semaglutide (Rybelsus)
  • Phentermine-topiramate (Qsymia)
  • Lifestyle modifications

Your questions

Pemvidutide FAQ

Why doesn't pemvidutide need a slow step-up in dose (dose titration)?

Pemvidutide activates two hormone receptors (GLP-1 (a gut hormone that tells your brain you're full) and glucagon) in an even 1:1 balance, and that profile makes it tolerable at full therapeutic doses right away. Other similar drugs lean heavily on GLP-1 activity, which causes severe early nausea and forces a slow dose ramp-up. Pemvidutide's balance allows therapeutic dosing from the first injection, which simplifies treatment and may help people stick with it early on.

What is the IMPACT trial and what did it show?

IMPACT was a Phase 2 randomized controlled trial of pemvidutide in patients whose MASH (a serious form of fatty liver disease) was confirmed by biopsy. At 24 weeks, the 1.2 mg dose resolved MASH — judged by examining liver tissue under a microscope — in 58% of patients, and liver fat fell by up to 75% on MRI scans. These results earned FDA Breakthrough Therapy and Fast Track designations.

How does pemvidutide compare to other drugs that act on two targets, like survodutide or mazdutide?

Pemvidutide stands out in three ways: it activates the GLP-1 (a gut hormone that tells your brain you're full) and glucagon receptors in an even 1:1 balance (some competitors lean mostly on GLP-1); it needs no gradual dose ramp-up, which simplifies starting treatment; and it uses EuPort technology, which attaches a sugar-fat molecule to the peptide to make it last longer (versus the usual fatty-acid attachment). It is currently in Phase 2b/3 trials, while survodutide and mazdutide are further along. The drugs have not been compared head to head.

Is pemvidutide FDA approved?

No. As of early 2026, pemvidutide is an investigational compound in Phase 2b/3 clinical development. It has received FDA Breakthrough Therapy designation and Fast Track designation for MASH, which may accelerate the regulatory review process. Phase 3 trials (VENTURE program) are underway for both obesity and MASH indications.

What is EuPort technology (a sugar-and-fat molecule attached to the drug)?

EuPort is Altimmune's proprietary glycolipid conjugation platform that covalently attaches a glycolipid moiety to the peptide. This modification enables strong non-covalent binding to serum albumin in circulation, which shields the peptide from enzymatic degradation and renal clearance. The result is a half-life (how long it stays active in your body) of approximately 110 hours (4.6 days), supporting once-weekly subcutaneous (under the skin) administration.

What weight loss was achieved in clinical trials?

In the Phase 2b MOMENTUM trial, pemvidutide 2.4 mg achieved approximately 15.6% placebo-adjusted mean body weight loss at 48 weeks in adults with obesity or overweight. The 1.8 mg dose achieved approximately 13.0% weight loss. These results were achieved without dose titration (stepping the dose up gradually), meaning the full therapeutic effect began from the first injection.

7 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the Pemvidutide research profile on Peptide Initiative.

  1. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyNoureddin M, et al. · 2025
  2. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trialBrowne SK, et al. · 2025
  3. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled studyHarrison SA, et al. · 2025
  4. Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugsKaya E, et al. · 2025
  5. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitisNestor JJ, et al. · 2022
  6. 262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity - A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) TrialAronne L, Harris MS, Roberts MS, Suschak JJ, Tomah S, Kasper J, He L, Yang J, Frias JP, Browne SK · 2024
  7. Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASHAltimmune, Inc. · 2025

Want the deep science?

Read the full Pemvidutide research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More weight loss guides

This guide is education, not medical advice. Pemvidutide is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.